Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
Keywords :
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Contact Email
Phone number
Website URL
Similar Companies1000
Aldeyra Therapeutics
Aldeyra Therapeutics is a biotechnology company that develops and commercializes next-generation medicines for immune-mediated diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
Viridian Therapeutics
Viridian Therapeutics is developing new treatments for serious diseases.
Sector
Subsector
Location
total rounds
total raised
1st Biotherapeutics
1STBIO develops breakthrough therapies to provide novel medicines to patients.
Sector
Subsector
Location
total rounds
total raised
Kyverna Therapeutics
Kyverna Therapeutics is a company that is developing new therapies and cures for serious autoimmune diseases.
Sector
Subsector
Location
total rounds
total raised
Financials
Funding Rounds9
Number of Funding Rounds
Money Raised
Their latest funding was raised on 08.01.2024. Their latest round Post-IPO Equity
Co-Investors
Investors8
Number of lead investors
Number of investors
Domain Associates
Domain Associates is a venture capital firm that invests exclusively in life sciences.
Sector
Subsector
Location
count Of Investments
count Of Exists
Eckard Weber
Eckard Weber, M.D. is a co-founder of Ocera and served as a member of its board of directors since Ocera’s inception in December 2004, and as the chairman of Ocera’s board of directors since March 2004. Dr. Weber is also an employee of Domain Associates, L.L.C., a private venture capital management firm focused on life sciences, a position he has held since 2001. Dr. Weber currently serves as interim chief executive officer of Sonexa Therapeutics, a seed-stage biopharmaceutical company. He is chairman of the board at Ascenta Therapeutics, Inc., Ocera Therapeutics Inc., Sequel Pharmaceuticals, Inc., Tobira Therapeutics, Inc. and Tragara Pharmaceuticals, Inc. Dr. Weber is an observer on the board of directors of Syndax Pharmaceuticals, Inc. and a member of the board of directors of Adynxx, Inc., Domain Elite Holdings, Ltd., and RightCare Solutions, Inc. Dr. Weber was chairman of Peninsula Pharmaceuticals, Inc. until the company was sold to Johnson & Johnson in 2005, chairman of Cerexa Inc. until the company was sold to Forest Laboratories, Inc. in January 2007, chairman of NovaCardia, Inc. until the company was sold to Merck in September 2007, chairman of Calixa Therapeutics until the company was sold to Cubist Pharmaceuticals in December 2009 and a board member of Conforma Therapeutics Corporation and Cabrellis Pharmaceuticals Corporation until they were sold to Biogen-IDEC, Inc. and Pharmion Corporation, respectively. Dr. Weber also has over 20 years of drug discovery and development experience and has been a consultant to biotechnology and pharmaceutical companies. Until 1995, he was a tenured Professor of Pharmacology at the University of California, Irvine. Dr. Weber is the inventor or co-inventor of over 40 patents and patent applications, and as published over 130 papers in scientific periodicals. Dr. Weber is a member of the board of director of Orexigen, Inc., and, during the past five years, served as a member of the board of directors of Novacea, Inc., each of which is a publicly traded company. Dr. Weber holds a B.S. from Kolping College in Germany and an M.D. from the University of Ulm Medical School in Germany.
current job
Kleiner Perkins
Kleiner Perkins is a venture capital firm that invests in early-stage, incubation and growth companies.
Sector
Subsector
Location
count Of Investments
count Of Exists
Beth Seidenberg
Beth Seidenberg is a partner at Kleiner Perkins Caufield & Byers focused on life science investing. She works with entrepreneurs to develop companies with breakthrough technology for treating patients and improving health. Since joining KPCB in 2005, Beth has incubated five companies and serves on the board of directors of 3-V Biosciences, Armo Biosciences, Atara, Auxogyn, Breathe Technologies, Epizyme, iPierian, Redbrick Health and TESARO. Before joining KPCB, Beth was senior vice president of development and chief medical officer of Amgen, Inc. Earlier in her career, she was a senior executive in research and development at Bristol-Myers Squibb Co. and Merck & Co., Inc. Under her leadership, 10 innovative products were developed and marketed globally and achieved more than 40 regulatory approvals. Beth received her B.S. degree from Barnard College and her M.D. from the University of Miami. She completed her post-graduate training at Johns Hopkins University, George Washington University and the National Institutes of Health.
current job
Amgen Ventures
Amgen Ventures is a biotech-focused venture capital firm.
Sector
Subsector
Location
count Of Investments
count Of Exists
People
Founders1
Isaac Ciechanover
Isaac Ciechanover is a physician, investor and entrepreneur driven by a passion to improve the practice of medicine. Motivated by the belief that the majority of medical discoveries still lie ahead, he has dedicated the past 20 years to working with entrepreneurs and life sciences organizations to advance medicine through innovation and technology. He founded Atara Biotherapeutics in October 2012. Previously, he was a partner in the life sciences practice at Kleiner Perkins Caufield & Byers. Earlier as Celgene’s Executive Director in Business Development, he spearheaded the company’s venture capital efforts and led licensing and M&A activities with an aggregate value of more than $6.7 billion. Also at Celgene, he was Global Project Leader for the company’s first clinical-stage biologic therapy. Isaac has also held business development and venture capital roles at Amylin Pharmaceuticals, Pequot Ventures’ healthcare practice and Pfizer. Intellectually curious (and undeterred by student debt), Isaac holds a B.A. in Psychology from Stanford University, an M.Phil. in Epidemiology from Cambridge University, an M.D. from Weill Cornell Medical College and an MBA from Harvard Business School. For fun, he enjoys cycling, scuba diving and building Lego with his two children. His all-time favorite albums are Pink Floyd’s “The Dark Side of the Moon,” Radiohead’s “OK Computer” and Ruggero Leoncavallo’s Italian opera, Pagliacci, with Herbet Von Karajan conducting.
current job
Isaac Ciechanover
Employee Profiles86
Lisa Schantz
Senior director, people business partner
Mark Ekdahl
Associate director, research program management
Aaron Villaroya
Senior director, strategy and operations
Judy Mchugh
Director, supply chain business systems
Chris Wilkinson
Director, global program management
Maribel Hines
Senior director, global talent development
Maria Maravilla
Logistics manager, global supply chain
Activity
Recent News33
The graph reveals the ratio (%) of positive news articles in a chosen time range